Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

High-throughput gene expression profiling of human castration-resistant prostate cancer cell lines

ABSTRACT: We examine the gene expression and chromatin accessibility profiles of four human castration-resistant prostate cancer cell lines including two representative of small-cell neuroendocrine prostate cancer

ORGANISM(S): Homo sapiens

PROVIDER: GSE154575 | GEO | 2020/07/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

High-throughput chromatin accessibility profiling of human castration-resistant prostate cancer cell lines

Project description:We examine the gene expression and chromatin accessibility profiles of four human castration-resistant prostate cancer cell lines including two representative of small-cell neuroendocrine prostate cancer

2020-07-17 | GSE154574 | GEO

GATA2 shRNA Expression in Castration Resistant Prostate Cancer Cell Lines

2014-11-04 | GSE58966 | GEO

GATA2 shRNA Expression in Castration Resistant Prostate Cancer Cell Lines

Project description:The transcription factor GATA2 regulates chemotherapy resistance in prostate cancer. We report a novel GATA2 transcriptional program that has implications for chemotherapy resistance disease and aggressiveness in castration resistant prostate cancer. Examination of the transcriptional network changes induced in human Ch-CRPC cell lines by two shRNA mediated knock down of GATA2 versus random shRNA control

2014-11-04 | E-GEOD-58966 | biostudies-arrayexpress

Mitoribosome sensitivity to HSP70 inhibition uncovers metabolic liabilities of castration-resistant prostate cancer

Project description:TMT-MS of whole cell lysate collected from 22Rv1 castration-resistant prostate cancer cells treated with 5 µM JG-98 for 4 hours.

2023-04-25 | PXD038684 | JPOST Repository

RNA-seq of human prostate cancer cell lines grown as orthotopic tumour models of castration resistant prostate cancer

Project description:To identify changes at multiple omic levels between hormone naive and castration resistant prostate cancer. Using orthograft murine tumour models of human cell lines injected into the prostate of CD-1 Nude mice grown under castration resistant (castrate) or hormone naive (non-castrate) conditions.

2021-05-03 | E-MTAB-9831 | biostudies-arrayexpress

High-throughput profiling of human castration-resistant prostate cancer cell lines

Project description:High-throughput profiling of human castration-resistant prostate cancer cell lines

| PRJNA646715 | ENA

Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer

Project description:Androgen receptor (AR) pathway inhibition remains the cornerstone for first- and second-line prostate cancer therapies. Although AR signaling inhibitors, such as enzalutamide and abiraterone extend survival in recurrent and castration-resistant prostate cancer (CRPC), durable and complete responses are rare. Resistance mechanisms employed by metastatic CRPC include amplification of AR and AR splice variants in AR-positive CRPC (ARPC) and conversion to AR-null phenotypes, such as double-negative prostate cancer (DNPC) and small cell or neuroendocrine prostate cancer (SCNPC). We have shown previously that DNPC can bypass AR-dependence through fibroblast growth factor (FGF) signaling. However, the role of the fibroblast growth factor receptor (FGFR) pathway in other molecular subtypes of CRPC has not been elucidated.

2023-09-19 | GSE228283 | GEO

Phospo-proteomic profiling of Castration Resistant Prostate Cancer

Project description:The integration of diverse ‘omic’ datasets will increase our understanding of the key signaling pathways that drive disease. Here, we used clinical tissue cohorts corresponding to lethal metastatic castration resistant prostate cancer (CRPC) obtained at rapid autopsy to integrate mutational, transcriptomic, and phosphoproteomic datasets for pathway analysis. Using Tied Diffusion through Interacting Events (TieDIE), we integrated differentially expressed transcriptional master regulators, functionally mutated genes, and differentially ‘activated’ kinases in CRPC tissues to synthesize a robust signaling network consisting of pathways with known and novel gene interactions. For 6 individual CRPC patients for which we had transcriptomic and phosphoproteomic data we observed distinct pathway activation states for each patient profile. In one patient, the activated pathways were strikingly similar to a prostate cancer cell line, 22Rv1, providing us with a good pre-clinical model to test targeted, combination therapies. In all, synthesis of multiple ‘omic’ datasets revealed a plethora of pathway information suitable for targeted therapies in lethal prostate cancer.

2016-08-19 | PXD002286 | Pride

A whole-blood RNA transcript based prognostic model in castration-resistant prostate cancer

Project description:Peripheral blood from 62 men with castration resistant prostate cancer was collected between 8/2006 and 6/2008. A panel of 168 inflammation-related and prostate cancer related genes was assessed with quantitative PCR to assess biomarkers predictive of survival. qPCR profiling of whole blood from patients with castration-resistant prostate cancer.

2013-04-02 | E-GEOD-45705 | biostudies-arrayexpress

A landscape of circular RNAs expression in the castration-resistant prostate cancer

Project description:Prostate cancer is one of the major cancers that seriously affect men's health. It has high morbidity and high mortality, but there is still no ideal molecular markers for the diagnosis and prognosis of prostate cancer. Castration-resistant prostate cancer is associated with wide variations in survival. To determine whether differentially expressed circRNAs in plasma exosomes can be used as a novel biomarker for castration-resistant prostate cancer prognosis, we performed high-throughput circRNA sequencing on 15 pairs of plasma exosomes from 30 metastatic castration-resistant prostate cancer patients, with or without early progression, to screen differentially expressed circRNAs.

2023-04-05 | GSE125256 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data